Virtual screening and lead optimisation to identify novel inhibitors for
  HDAC-8 by JE, Maria Antony Dhivyan & MN, Anoop
 1 
VIRTUAL SCREENING AND LEAD OPTIMIZATION TO IDENTIFY 
NOVEL INHIBITORS FOR HDAC-8 
 
Maria Antony Dhivyan JE and Anoop MN 
School of Health and Life Sciences, Edinburgh Napier University, Edinburgh, United 
Kingdom – EH10 5DT 
 
                                                 ABSTRACT 
 
Histone deacetylase (HDAC) and Histone acetyl-transferase (HAT) are enzymes that 
influence transcription by selectively deacetylating or acetylating the ε-amino groups 
of lysine located near the amino termini of core histone proteins. Over expression of 
HDACs noted in many forms of cancers including leukemia and breast cancer. HDAC 
inhibitors have been shown to be potent inducers of growth arrest, differentiation, 
and/or apoptotic cell death. There is a growing interest in the development of histone 
deacetylase inhibitors as anti cancer agents. Three known ligands of HDAC-8 were 
taken and docked. The best scores were analyzed and structures similar to these 
ligands were downloaded using c@rol and corina databases and docked. Also large 
databases of small molecules were computationally screened using molecular     
docking for “hits” that can conformationally and chemically fit to the active site. 
Molecules which got high scores for both GoldScore and ChemScore were selected 
and compared with the previous results. Those with best results were then taken for 
calculating H-bond interactions and close contacts. Bioactivity prediction of the best 
ranked ligands was done. Their physicochemical properties were also analyzed. Four 
new molecules were identified and suggested for further testing in the wet lab. 
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INTRODUCTION 
 
         Bioinformatics involve the use of techniques including applied mathematics, 
informatics, statistics, computer science, artificial intelligence, chemistry, and 
biochemistry to solve biological problems usually on the molecular level. Major 
research efforts in the field include sequence alignment, gene finding, genome 
assembly, protein structure alignment, protein structure prediction, prediction of gene 
expression and protein-protein interactions, and the modeling of evolution. 
     Bioinformatics can influence significantly in solving the following types of 
problems: 
1. Prediction of 3-D structure based on linear genomic information, i.e., the study 
of structural genomics. 
2. Gene expression analysis, prediction of gene function and establishment of 
gene libraries (functional genomics). 
3. The ability to use genome sequence to identify proteins and their functions, 
protein interactions, modifications and functions, i.e., the field of proteomics. 
4. Simulating metabolism from the biochemical functions of an organism. 
5. Molecular modeling and molecular dynamics are the methods to predict 
structure from experimental data. 
6. Data obtained from functional genomics and proteomics could be used in drug 
designing and discovery. 
       
       With the near completion of the human genome sequencing, bioinformatics has 
established itself as an essential tool in target discovery and the insilico analysis of 
gene expression and gene function are now an integral part of it, facilitating the 
selection of the most relevant targets for a disease under study. 
       A bulk of techniques, both old and new, has recently matured into potent 
weapons in the war against disease. The need for ongoing development of new drugs 
needs no emphasis in the light of the current global situation of health and disease 
 
Drug discovery research relies heavily on bioinformatics to manage the databases of 
small molecules that are potential lead compounds, to search databases of protein 
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structures for structure-based drug design methods, and to model the docking of 
compounds and their target proteins. 
 
The need for ongoing development of new drugs needs to emphasis in light of the 
current global situation of health and disease. Traditionally, the process of drug 
development has revolved around a screening approach, as nobody knows which 
compound or approach could serve as a drug or therapy. Such almost blind screening 
approach is very time-consuming and laborious. The short coming of traditional drug 
discovery; as well as the allure of a more deterministic approach to combating 
disease has led to the concept of “Rational drug design”(Kuntz 1992). 
 
Nobody could design a drug before knowing more about the disease or infectious 
process than past. For “rational” design, the first necessary step is the identification of 
a molecular target critical to a disease process or an infectious pathogen. Then the 
important prerequisite of “drug design” is the determination of the molecular structure 
of target, which makes sense of the word “rational”. In fact, the validity of “rational” or 
“structure-based” drug discovery rests largely on a high-resolution target structure of 
sufficient molecule detail to allow selectivity in the screening of compounds. 
 
 1.1   COMPUTER-AIDED DRUG DESIGN (CADD) 
 
Computer-aided drug design (CADD), is also called computer-aided molecular design 
(CAMD), represents more recent applications of computer as tools in the drug design 
process. This field includes computer graphics, 3-D model of molecules (Molecular 
Modeling), protein structure prediction and analysis, molecular motion (Molecular 
dynamic simulation), molecular shape(conformational analysis), molecular property 
prediction, quantitative structure/property relationships (QSAR/QSPR), database 
search, quantum chemistry(for predicting structure properties and reactivity), 
computer assisted synthesis, protein/drug “docking” etc. the techniques provided by 
computational methods include computer graphics for visualization and the 
methodology of theoretical chemistry. 
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The development of new drugs with potential therapeutic applications is one of the 
most complex and difficult process in the pharmaceutical industry. Millions of dollars 
and man-hours are devoted to the discovery of new therapeutic agents. As, the 
activity of a drug is the result of a multitude of factors; rational drug design has been 
utopias for centuries. Computers have magnified the capability of scientists to collect, 
access, and analyze information, and even do “virtual” experiments. Recently 
Computer-based drug design (CADD) has caused a “quiet explosion” in modern drug 
discovery. CADD can guide and assist the design of new therapeutic agents with 
desired properties by means of molecular modeling, theoretical calculation and 
prediction methods. The aim of using the computer for drug design is to analyze the 
interactions between the drug and its receptor site and to “design” molecules that give 
an optimal fit. The central assumption is that a good fit results from structural and 
chemical complementarities to the target receptor. 
 
The steps involved are: 
 
1.1.1    TARGET IDENTIFICATION 
 
This step aims to identify a biological drug target. This is typically a receptor, enzyme 
or ion channel that needs to be manipulated to prevent the development of a disease 
or alleviate symptoms. Drug usually act on either cellular or genetic chemicals in the 
body, known as targets, which are believed to be associated with disease. Scientists 
use a variety of techniques to identify and isolate a target and learn more about its 
functions and how these influence disease. Compounds are then identified that have 
various interactions with drug targets helpful in treatment of a specific disease. Thus, 
we concentrate our efforts on discovering or even inventing compounds that can alter 
the disease-causing mechanism, whether a single protein or a complex pathway of 
proteins, to bring it back into line with normal function. 
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1.1.2     TARGET VALIDATION 
 
To select targets most likely to be useful in the development of new treatments for 
disease, researchers analyze and compare each drug target to others based on their 
association with a specific disease and their ability to regulate biological and chemical 
compounds in the body. Tests are conducted to confirm that interactions with the drug 
target are associated with a desired change in the behavior of diseased cells. 
Research scientists can then identify compounds that have an effect on the target 
selected. 
 
 
1.1.3     LEAD IDENTIFICATION 
 
A lead compound or substance is one that believed to have potential to treat disease. 
Laboratory scientists can compare known substance with new compounds to 
determine their likelihood of success. Leads are sometimes developed as collections, 
or libraries, of individual molecules that possess properties needed in a new drug. 
The most important source of leads is “libraries” of molecule (e.g.) natural product 
libraries, peptide libraries, carbohydrates libraries, etc. “Virtual libraries” can be 
created by using combinatorial chemistry. Testing is then done on each of these 
molecules to confirm its effect on the drug target. 
Some of the technologies used in the lead identification are: 
 
1. Virtual screening 
2. High throughput docking 
 
1.1.3.1     VIRTUAL SCREENING 
 
The dominant technique for the identification of new lead compounds in drug 
discovery is the physical screening of large libraries of chemicals against a biological 
target (high throughput screening). Virtual screening is an alternative approach is to 
computationally screen large libraries of chemicals for compounds that complement 
targets of known structure, and experimentally test those that are predicted to bind 
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well. It access a large number of possible new ligands which can be purchased and 
tested. Virtual screening, or insilico screening, is a new approach attracting increasing 
levels of interest in the pharmaceutical industry as a productive and cost-effective 
technology in the search for novel lead compounds. Although the principles involved-
the computational analysis of chemical databases to identify compounds appropriate 
for a given biological receptor-have been pursued for several years in molecular 
modeling groups, the availability of inexpensive high-performance computing 
platforms has transformed the process so that increasingly complex and more 
accurate analyses can be performed on very detailed and relevant basis for 
prioritizing compounds for biological screening. Virtual screening offers a practical 
route to discovering new reagents and lead for pharmaceutical research.  
 
  1.1.3.2    HIGH THROUGHPUT DOCKING: 
 
        Docking is research technique for predicting whether one molecule will bind to 
another, usually a protein. Docking is a term used for computational schemes that 
attempt to find the best matching between two molecules: receptor and a ligand. If the 
geometry of the pair is complimentary and involves favorable biochemical 
interactions, the ligand will potentially bind the protein (receptor). 
 
1.1.4     LEAD OPTIMIZATION: 
         Lead optimization compares the properties of various lead compounds and 
provides information to select the compound or compounds with the greatest potential 
to be developed into safe and effective medicines. The candidate drugs with better 
therapeutic profiles are accessed for quality, taking into account factors such as the 
ease of synthesis and formulation. After this they are registered as an investigational 
new drug and submitted for clinical drug. 
 
1.1.5    TESTING OF THE ACTIVE COMPOUND (PRE-CLINICAL PHASE) 
          After optimizing the active compound, testing in the preclinical phase lab and 
animal testing is used to verify whether it is principally suited for use in the human 
body. To determine this, the researchers examine among other things how the 
compound is absorbed by the body, how it is excreted, and how it affects the organs. 
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In addition, they examine whether and in concentration it has a toxic or effect on the 
genetic makeup. 
 
1.1.6     CLINICAL TRIALS 
           If the active compound proves successful and also fulfils the legal 
requirements, it is then directly tested on human beings in three clinical phases: 
Phase 1: Compatibility in health test subjects 
Phase 2: Determination of optimal doses 
Phase 3: Proof of effectiveness. 
 
1.1.7      APPROVAL PROCESS 
             If the medicine has made its way through all of the preceding phases, the 
process of getting approval from the authorities begins. The drug cannot be marketed 
until approval has been obtained. 
                                      
                                 Target identification 
       ↓ 
 
                                 Target validation 
                                                      
 
                                  Lead identification 
 
 
                                  Lead optimization 
 
 
                                 Clinical trials 
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1.2   DRUG 
 
Drug is defined as "a chemical substance used in the treatment, cure, prevention, or 
diagnosis of disease or used to otherwise enhance physical or mental well-being. 
Drugs may be prescribed for a limited duration, or on a regular basis for chronic 
disorders. 
 
1.3    TARGET 
 
A drug target is a key molecule involved in a particular metabolic or signaling pathway 
that is specific to a disease condition or pathology, or to the infectivity or survival of a 
microbial pathogen. Drugs are used to stop the functioning of the pathway in the 
diseased state by causing a key molecule to stop functioning. Drugs may be designed 
that bind to the active region and inhibit this key molecule. 
 
1.4     LIGAND  
 
A ligand is a molecule that is able to bind  and form a complex with a biomolecule to 
serve a biological purpose. It is an effector molecule binding to a site on a target 
protein, by intermolecular forces such as ionic bonds, hydrogen bonds and Van der 
Waal forces. The docking (association) is usually reversible (dissociation). Actual 
irreversible covalent binding between a ligand and its target molecule is rare in 
biological systems.. Ligand binding to receptors alters the chemical conformation, i.e. 
the three dimensional shape of the receptor protein. The conformational state of a 
receptor protein determines the functional state of a receptor. The tendency or 
strength of binding is called affinity. Ligands include substrates, inhibitors, activators, 
and neurotransmitters. 
 
1.5     IC50 
 
The IC50 is a measure of drug effectiveness. It indicates how much of a particular 
drug or other substance (inhibitor) is needed to inhibit a given biological process by 
half. In other words, it is the half maximal (50%) inhibitory concentration (IC) of a 
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substance (50% IC, or IC50). It is commonly used as a measure of antagonist drug 
potency in pharmacological research. IC50 represents the concentration of a drug that 
is required for 50% inhibition in vitro. 
 
1.6     DOCKING 
 
Docking is the process by which two molecules fit together in 3D space. Docking is a 
method which predicts the preferred orientation of one molecule to a second when 
bound to each other to form a stable complex. Docking is frequently used to predict 
the binding orientation of small molecule drug candidates to their protein targets in 
order to in turn predict the affinity and activity of the small molecule. Hence docking 
plays an important role in the rational design of drugs. Molecular docking may be 
defined as an optimization problem, which would describe the “best-fit” orientation of 
a ligand that binds to a particular protein of interest. 
The focus of molecular docking is to computationally stimulate the molecular 
recognition process. The aim of molecular docking is to achieve an optimized 
conformation for both the protein and ligand and relative orientation between protein 
and ligand such that the free energy of the overall system is minimized. 
 
1.6.1     APPROACHES TO MOLECULAR DOCKING 
 
Two approaches are particularly popular within the molecular docking community. 
One approach uses a matching technique that describes the protein and the ligand as 
complementary surfaces. The second approach simulates the actual docking process 
in which the ligand-protein pair wise interaction energies are calculated. Both 
approaches have significant advantages as well as some limitations.  
 
1.6.1.1    SHAPE COMPLEMENTARITY METHODS 
 
Geometric matching/ shape compelementarity methods describe the protein and 
ligand as a set of features that make them dockable. These features may include 
molecular surface/ complementary surface descriptors. In this case, the receptor’s 
molecular surface is described in terms of its solvent-accessible surface area and the 
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ligand’s molecular surface is described in terms of its matching surface description. 
The complementarity between the two surfaces amounts to the shape matching 
description that may help finding the complementary pose of docking the target and 
the ligand molecules. Another approach is to describe the hydrophobic features of the 
protein using turns in the main-chain atoms. Yet another approach is to use a Fourier 
shape descriptor technique described in [ref]. Whereas the shape complementarity 
based approaches are typically fast and robust, they cannot usually model the 
movements or dynamic changes in the ligand/ protein conformations accurately, 
although recent developments allow these methods to investigate ligand flexibility. 
Shape complementarity methods can quickly scan through several thousand ligands 
in a matter of seconds and actually figure out whether they can bind at the protein’s 
active site, and are usually scalable to even protein-protein interactions. They are 
also much more amenable to pharmacophore based approaches, since they use 
geometric descriptions of the ligands to find optimal binding. 
 
1.6.1.2    SIMULATION PROCESSES 
 
The simulation of the docking process as such is a much more complicated process. 
In this approach, the protein and the ligand are separated by some physical distance, 
and the ligand finds its position into the protein’s active site after a certain number of 
“moves” in its conformational space. The moves incorporate rigid body 
transformations such as translations and rotations, as well as internal changes to the 
ligand’s structure including torsion angle rotations. Each of these moves in the 
conformation space of the ligand induces a total energetic cost of the system, and 
hence after every move the total energy of the system is calculated. The obvious 
advantage of the method is that it is more amenable to incorporating ligand flexibility 
into its modeling whereas shape complementarity techniques have to use some 
ingenious methods to incorporate flexibility in ligands. Another advantage is that the 
process is physically closer to what happens in reality, when the protein and ligand 
approach each other after molecular recognition. A clear disadvantage of this 
technique is that it takes longer time to evaluate the optimal pose of binding since 
they have to explore a rather large energy landscape. However grid-based 
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techniques as well as fast optimization methods have significantly ameliorated these 
problems. 
 
 1.6.2   THE MECHANICS OF DOCKING 
 
To perform a docking screen, the first requirement is a structure of the protein of 
interest. Usually the structure has been determined using a biophysical technique 
such as x-ray crystallography, or less often, NMR spectroscopy. This protein structure 
and a database of potential ligands serve as inputs to a docking program. The 
success of a docking program depends on two components: the search algorithm and 
the scoring function. 
 
 
Ligand database Target Protein 
 
Molecular docking 
 
Ligand docked into protein’s active site 
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1.6.3     APPLICATIONS OF DOCKING 
 
A binding interaction between a small molecule ligand and an enzyme protein may 
result in activation or inhibition of the enzyme. If the protein is a receptor, ligand 
binding may result in agonism or antagonism. Docking is most commonly used in the 
field of drug design— most drugs are small organic molecules, and docking may be 
applied to: 
• Hit identification - docking combined with a scoring function can be used to 
quickly screen large databases of potential drugs insilico to identify molecules that are 
likely to bind to protein target of interest (see virtual screening).  
• Lead optimization - docking can be used to predict in where and in which 
relative orientation a ligand binds to a protein (also referred to as the binding mode or 
pose). This information may in turn be used to design more potent and selective 
analogs. 
 
1.7     REVERSE DOCKING 
 
Ligand-protein docking has been developed and used in facilitating new drug 
discoveries. In this approach, docking single or multiple small molecules to a receptor 
site is attempted to find putative ligands. A number of studies have shown that 
docking algorithms are capable of finding ligands and binding conformations at a 
receptor site close to experimentally determined structures. These algorithms are 
expected to be equally applicable to the identification of multiple proteins to which a 
small molecule can bind or weakly bind. We introduce a ligand-protein inverse-
docking approach for finding potential protein targets of a small molecule by the 
computer-automated docking search of a protein cavity database. This database is 
developed from protein structures in the Protein Data Bank (PDB). Docking is 
conducted with a procedure involving multiple-conformer shape-matching alignment 
of a molecule to a cavity followed by molecular-mechanics torsion optimization and 
energy minimization on both the molecule and the protein residues at the binding 
region. Scoring is conducted by the evaluation of molecular-mechanics energy and, 
when applicable, by the further analysis of binding competitiveness against other 
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ligands that bind to the same receptor site in at least one PDB entry. The application 
of this approach may facilitate the prediction of unknown and secondary therapeutic 
target proteins and those related to the side effects and toxicity of a drug or drug 
candidate. 
 
1.8         THE SEARCH ALGORITHM 
 
The search space consists of all possible orientations and conformations of the 
protein paired with the ligand. With present computing resources, it is impossible to 
exhaustively explore the search space—this would involve enumerating all possible 
distortions of each molecule (molecules are dynamic and exist in an ensemble of 
conformational states) and all possible rotational and translational orientations of the 
ligand relative to the protein at a given level of granularity. Most docking programs in 
use account for a flexible ligand, and several are attempting to model a flexible 
protein receptor. Each "snapshot" of the pair is referred to as a pose. There are many 
strategies for sampling the search space. Here are some examples: 
• Use a coarse-grained molecular dynamics simulation to propose energetically 
reasonable poses  
• Use a "linear combination" of multiple structures determined for the same 
protein to emulate receptor flexibility  
• Use a genetic algorithm to "evolve" new poses that are successively more and 
more likely to represent favorable binding interactions.  
 
 1.9     THE SCORING FUNCTION 
 
The scoring function takes a pose as input and returns a number indicating the 
likelihood that the pose represents a favorable binding interaction. 
Most scoring functions are physics-based molecular mechanics force fields that 
estimate the energy of the pose; a low (negative) energy indicates a stable system 
and thus a likely binding interaction. An alternative approach is to derive a statistical 
potential for interactions from a large database of protein-ligand complexes, such as 
the Protein Data Bank, and evaluate the fit of the pose according to this inferred 
potential. 
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There are a lot of structures from X-ray diffraction for complexes between proteins 
and high affinity ligands, but very few for low affinity ligands as these do not stay 
bound for long enough to be seen. Scoring functions trained with this data can dock 
high affinity ligands correctly, but they will also give plausible docked conformations 
for ligands that really are inactive. This gives a large number of false positive hits, i.e., 
ligands predicted to bind to the proteins that actually don’t when placed together in a 
test tube. 
One way to reduce the number of false positives is to recalculate the energy of the 
top-hit poses using a higher resolution (and therefore slow) technique like 
Generalized Born or Poisson-Boltzmann methods. However, typically the researcher 
will screen a database of tens to hundreds of thousands of compounds and test the 
top 60 or so in vitro, and to identify any true binders is still considered a success. 
 
1.10    G-BIND: 
 
           It represents the free energy of binding,   Gbind. The G-bind value has to be 
low for a structure to be stable. ΔΔG = -RTlnK.  Binding (free) energy refers to that 
change in (free) energy for the following reaction: 
 
Protein (in water) + ligand (in water) ----> protein-ligand complex (in water)  
 
  One factor that can strongly influence predicted free energy of binding is the 
ionization state of functional groups on the ligands and at the binding site at which 
calculations are performed.         
   1.11    RMS: 
 
RMS refers to the Root Mean Squared Distance between the initial and final position 
of the ligand. The overall root mean square9RMS) deviation expression of any target 
molecule composed of m atoms in the training set may be written as a function of the 
parameters and geometry. 
 
       Rms=f(p1,p2,p3,……..,pm,x1,y1,z1,x2,y2,z2,….,xm,ym,zm) 
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       P1,p2,..,pm represent the complete set of force field parameters required for the 
molecular mechanics calculations of the structure. 
      X1,y1,z1,….,xm,ym,zm are the optimized Cartesian coordinates 
 
1.12     LOG P 
 
The logarithm of the ratio of the concentrations of the un-ionized solute in the solvents 
is called log P. Hydrophobicity is represented by LogP. Partition coefficient is the ratio 
of concentrations of a compound in the two phases of a mixture of two immiscible 
solvents at equilibrium. Hence it is a measure of differential solubility of the compound 
between these two solvents. Normally one of the solvents chosen is water while the 
second is hydrophobic such as octanol. Partition coefficients are useful in estimating 
the distribution of drugs within the body. Hydrophobic drugs with high partition 
coefficients are preferentially distributed to hydrophobic compartments such as lipid 
bilayers of cells while hydrophilic drugs (low partition coefficients) preferentially are 
found in hydrophilic compartments such as blood serum. 
 
1.13    LOGS 
 
The aqueous solubility of a compound is denoted as logs. It significantly affects its 
absorption and distribution characteristics. Typically, a low solubility goes along with a 
bad absorption and therefore the general aim is to avoid poorly soluble compounds. 
 
1.14    pKd:      
        The binding constant, pKd, is the negative logarithm of the inhibition constant Ki. 
The inhibitor constant, Ki, is an indication of how potent an inhibitor is; it is the 
concentration required to produce half maximum inhibition 
         Drug distribution within the body is determined mainly by free (unbound) 
concentration of drug in circulating plasma. The unbound fraction, in turn, depends on 
drug absorption by plasma proteins. Human Serum Albumin (HSA) is the most 
abundant blood plasma protein and is produced in the liver. HSA binding constants 
obtained by docking the molecule to both of the HSA active sites (Sudlow site I and 
Sudlow site II) are termed as Site1 pKd and site2 pKd respectively. 
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1.15     ALBUMIN PKD 
 
Drug distribution within the body is determined mainly by free (unbound) 
concentration of drug in circulating plasma. The unbound fraction, in turn, depends on 
drug absorption by plasma proteins. Human Serum Albumin (HSA) is the most 
abundant blood plasma protein and is produced in the liver. HSA normally constitutes 
about 60% of human plasma protein. HSA concentrations in blood plasma range from 
3.5 to 5.0g/l. It has been shown to shuttle a broad range of endogenous and 
exogenous ligands, including more than 70% of drugs. 
Binding of a drug to HSA results in an increased solubility in plasma, decreased 
toxicity, and /or protection against oxidation of the bound ligand. Binding can also 
have a significant impact on the pharmacokinetics of drugs. Q-Albumin software takes 
a molecular structure and calculates HSA binding constant by docking the molecule 
to both of the HSA active sites (Sudlow site I and Sudlow site II). 
 
 
1.16     DRUGLIKENESS  
 
Druglikeness may be defined as a complex balance of various molecular properties 
and structure features which determine whether particular molecule is similar to the 
known drugs. These properties, mainly hydrophobicity, electronic distribution, 
hydrogen bonding characteristics, molecule size and flexibility and presence of 
various pharmacophoric features influence the behavior of molecule in a living 
organism, including bioavailability, transport properties, affinity to proteins, reactivity, 
toxicity, metabolic stability and many others.  
 
1.17     LIPINSKI’S RULE 
 
Lipinski's Rule of Five is a rule of thumb to evaluate druglikeness. The rule states, 
that most "drug-like" molecules have logP <= 5, molecular weight <= 500, number of 
hydrogen bond acceptors <= 10, and number of hydrogen bond donors <= 5. 
Molecules violating more than one of these rules may have problems with 
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bioavailability. The rule is called "Rule of 5", because the border values are 5, 500, 
2*5, and 5.  The rule was formulated by Christopher A. Lipinski in 1997, based on the 
observation that most medication drugs are relatively small and lipophilic molecules. 
The rule describes molecular properties important for a drug's pharmacokinetics in 
the human body, including their absorption, distribution, metabolism, and excretion 
("ADME"). However, the rule does not predict if a compound is pharmacologically 
active. The modification of the molecular structure often leads to drugs with higher 
molecular weight, more rings, more rotatable bonds, and a higher lipophilicity    
 
1.18     HDAC-8 AS AN ANTI CANCER TARGET 
 
Histone deacetylase (HDAC) and histone acetyltransferase (HAT) are enzymes that 
influence transcription by selectively deacetylating or acetylating the ε-amino groups 
of lysine located near the amino termini of core histone proteins. Chromatin 
acetylation correlates with transcriptional activity (euchromatin), whereas 
deacetylation correlates with gene silencing. HDACs are also involved in the 
reversible acetylation of non-histone proteins. Altered HDAC and/or HAT activities are 
present in many types of cancers. 
 
Mammalian HDACs have been classified into three classes. Class I (HDACs 1, 2, 3 & 
8; each of which contains a deacetylase domain exhibiting from 45% to 93% identity 
in amino acid sequence) are homologs of yeast RPD3 and localize to the nucleus. 
Class II (HDACs 4, 5, 6, 7, 9 & 10) are homologs of yeast Hda1 and are found in both 
the nucleus and cytoplasm. The molecular weights of which are all about two fold 
larger than those of the class I members, and the deacetylase domains are present 
within the C-terminal regions, except that HDAC-6 contains two copies of the domain, 
one within each of the N-terminal and C-terminal regions. HDAC11 has properties of 
both class I and class II HDACs. Class III (Sirt1 - Sirt7) are homologs of yeast Sir2 
and form a structurally distinct class of NAD-dependent enzymes found in both the 
nucleus and cytoplasm.  
 
Conserved from yeast to human, HDAC classes I and II are inhibited by trichostatin A 
(Prod. No. 380-068) and appear to use a divalent zinc-binding motif. The metal-
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coordinated active site activates an H2O molecule for direct targeting and hydrolysis 
of the acetyl group to form acetate. Acetylation of lysines in histones neutralizes the 
positive electric charge between the negatively charged DNA backbone and tips the 
balance towards relaxing the chromatin, while deacetylation would shift the balance 
back to condensing the chromatin and silencing gene expression. In a similar way 
PARP-1 adds to histones hundreds of negatively charged ADP-ribose units, which 
repel histones away from the negatively charged DNA backbone and thus induces 
chromatin relaxation to facilitate accession of DNA repair enzymes and gene 
expression.  
 
HDAC inhibitors represent a relatively new group of targeted anticancer compounds, 
which are showing significant promise as agents with activity against a broad 
spectrum of neoplasms, at doses that are well tolerated by cancer patients. A number 
of small molecule inhibitors of HDAC, such as naturally occurring Trichostatin A 
(TSA), as well as synthetic compounds such as Suberoylanilide hydroxamic acid 
(SAHA), Scriptaid, Oxamflatin etc have been reported to induce differentiation of 
several cancer cell lines and suppress cell proliferation. But most of the inhibitors 
developed till date, including TSA and SAHA are derivatives of hydroxamic acid and 
are associated with poor pharmacokinetics and severe toxicity. They do not 
discriminate well among HDAC isozymes. Thus, there is a considerable interest in 
developing new non-hydroxamate HDAC inhibitors with few side effects. 
 
Inhibitors of HDAC classes I and II emerge as potent anti-cancer agents. A proposed 
mechanism for the anti-tumor effects of HDAC inhibitors is that the accumulation of 
acetylated histones leads to activation (and repression) of the transcription of a 
selected number of genes whose expression causes inhibition of tumor cell growth 
and induction of apoptosis.  
 
Disruption of HDACs has been linked to a wide variety of human cancers. HDAC 
inhibitors have been shown to be potent inducers of growth arrest, differentiation, 
and/or apoptotic cell death. Some newly synthesized compounds are potentially 
effective agents for cancer therapy and, possibly, cancer chemoprevention. 
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Figure-1: Structure of HDAC-8 with SAHA (in blue). 
 
 
1.18.1 Classes of HDACs in higher eukaryotes 
 
HDACs are classified in four classes depending on sequence identity and domain 
organization. 
• Class I  
 HDAC1, HDAC2, HDAC3, HDAC8  
• Class II  
 HDAC4, HDAC5, HDAC6, HDAC7A, HDAC9, HDAC10  
• Class III  
 Homologs of Sir2 in the yeast Saccharomyces cerevisiae  
 Sirtuins in mammals (SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7)  
• Class IV  
 HDAC11 
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1.18.2    TRICHOSTATIN A 
 
Trichostatin A is an organic compound that serves as an antifungal antibiotic and 
selectively inhibits the mammalian histone deacetylase family of enzymes. TSA 
inhibits the eukaryotic cell cycle during the beginning of the growth stage. TSA can be 
used to alter gene expression by interfering with the removal of acetyl groups from 
histones and therefore altering the ability of DNA transcription factors to access the 
DNA molecules inside chromatin. Thus, TSA has some uses as an anti-cancer drug. 
By promoting the expression of apoptosis-related genes, it may lead to cancerous 
cells surviving at lower rates, thus slowing the progression of cancer. Trichostatin A is 
harmful by inhalation, in contact with skin and if swallowed irritating to eyes, 
respiratory system and skin. Trichostatin A may cause sensitization by skin contact. 
 
1.18.3     SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) 
 
Suberoylanilide hydroxamic acid (SAHA) is a novel histone deacetylase inhibitor with 
high potency in inducing differentiation of cultured murine erythroleukemia cells. 
SAHA induces cell cycle arrest and apoptosis in human breast cancer cells. SAHA 
reduces glioma progression in the organotypic brain environment. 
 
1.18.4       SCRIPTAID 
 
A novel histone deacetylase inhibitor, Scriptaid, enhances expression of functional 
estrogen receptor α (ER) in ER negative human breast cancer cells in combination 
with 5-aza 2′-deoxycytidine. The use of scriptaid resulted in a >100-fold increase in 
histone acetylation (Fig. 4) in cultured cells, which confirmed scriptaid as a HDAC 
inhibitor.  
 
1.18.5      OXAMFLATIN 
 
Oxamflatin is a novel antitumor compound that inhibits mammalian histone 
deacetylase. Oxamflatin caused an elongated cell shape with filamentous protrusions 
as well as arrest of the cell cycle at the G1 phase in HeLa cells. These phenotypic 
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changes of HeLa cells were apparently similar to those by trichostatin A (TSA), a 
specific inhibitor of histone deacetylase (HDAC). Oxamflatin, like TSA, inhibited 
intracellular HDAC activity, as a result of which marked amounts of acetylated histone 
species accumulated. Oxamflatin induced the morphological changes of human cell 
lines characteristic of cells treated with TSA and other HDAC inhibitors during the 
experiments of in vitro cytotoxicity.  Most of the inhibitors developed till date, including 
TSA and SAHA are derivatives of hydroxamic acid and are associated with poor 
pharmacokinetics and severe toxicity. They do not discriminate well among HDAC 
isozymes. 
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                                           AIM AND SCOPE 
 
To identify novel potential ligands for HDAC-8 from a set of virtually screened 
molecules. 
To calculate the drug likeness and IC50 of the novel potential ligands. 
To optimize the novel potential ligands. 
 
HDAC inhibitors have been shown to be potent inducers of growth arrest, 
differentiation, and/or apoptotic cell death. HDAC inhibitors also represent a relatively 
new group of targeted anticancer compounds, which are showing significant promise 
as agents with activity against a broad spectrum of neoplasms, at doses that are well 
tolerated by cancer patients. A number of small molecule inhibitors of HDAC, such as 
naturally occurring Trichostatin A (TSA), as well as synthetic compounds such as 
Suberoylanilide hydroxamic acid (SAHA), Scriptaid, Oxamflatin etc have been 
reported to induce differentiation of several cancer cell lines and suppress cell 
proliferation. But most of the inhibitors developed till date, including TSA and SAHA 
are derivatives of hydroxamic acid and are associated with poor pharmacokinetics 
and severe toxicity. They do not discriminate well among HDAC isozymes. Thus, 
there is a considerable interest in developing new non-hydroxamate HDAC inhibitors 
with few side effects. 
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                                  MATERIALS AND METHODS 
 
MATERIALS 
3.1     PROTEIN DATA BANK (http://www.rcsb.org) 
 
The Protein Data Bank (PDB) is a repository for 3-D structural data of proteins and 
nucleic acids. These data typically obtained by X-ray crystallography or NMR 
spectroscopy and submitted by biologists and biochemists from around the world, are 
released into the public domain, and can be accessed for free. 
The database contained 39,051 released atomic coordinate entries (or "structures"), 
35,767 of that proteins, the rest being nucleic acids, nucleic acid-protein complexes, 
and a few other molecules. About 5,000 new structures are released each year. Data 
are stored in the mmCIF format specifically developed for the purpose. 
The database stores information about the exact location of all atoms in a large 
biomolecule (although, usually without the hydrogen atoms, as their positions are 
more of a statistical estimate); if one is only interested in sequence data, i.e. the list of 
amino acids making up a particular protein or the list of nucleotides making up a 
particular nucleic acid, the much larger databases from Swiss-Prot and the 
International Nucleotide Sequence Database Collaboration should be used. 
The structural data can be used to visualize the biomolecules with appropriate 
software, such as VMD, RasMol, PyMOL, Jmol, MDL Chime, QuteMol, web browser 
VRML plugin or any web-based software designed to visualize and analyze the 
protein structures such as STING. A recent desktop software addition is Sirius. The 
RCSB PDB website also contains resources for education, structural genomics, and 
related software. 
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3.2      SWISS PDB VIEWER (http://www.expasy.org/spdbv/) 
 
DeepView - Swiss-PdbViewer is an application that provides a user friendly interface 
allowing to analyze several proteins at the same time. The proteins can be 
superimposed in order to deduce structural alignments and compare their active sites 
or any other relevant parts. Amino acid mutations, H-bonds, angles and distances 
between atoms are easy to obtain. DeepView - Swiss-PdbViewer has been 
developed by Nicolas Guex (GlaxoSmithKline R&D). Swiss-PdbViewer is tightly 
linked to SWISS-MODEL, an automated homology modeling server developed within 
the Swiss Institute of Bioinformatics (SIB) at the Structural Bioinformatics Group at 
the Biozentrum in Basel. 
Working with these two programs greatly reduces the amount of work necessary to 
generate models, as it is possible to thread a protein primary sequence onto a 3D 
template and get an immediate feedback of how well the threaded protein will be 
accepted by the reference structure before submitting a request to build missing loops 
and refine side chain packing. 
Swiss-PdbViewer can also read electron density maps, and provides various tools to 
build into the density. In addition, various modeling tools are integrated and command 
files for popular energy minimization packages can be generated. 
 
3.3     PYMOL (www.pymol.org)  
 
PyMOL is a user-sponsored molecular visualization system on an open-source 
foundation. It was created by Warren Lyford Delano and commercialized by Delano 
Scientific LLC, which is a private software company dedicated to creating useful tools 
that become universally accessible to scientific and educational communities. It is 
well suited to producing high quality 3D images of small molecules and biological 
macromolecules such as proteins. PYMOL is one of few open source visualization 
tools available for use in structural biology. The Py portion of the software’s name 
refers to the fact that it extends, and is extensible by, the Python programming 
language. 
 
 
 25 
3.4       ARGUSLAB (http://www.planaria-software.com) 
 
Arguslab is a free program for calculating the docking modes of small molecules into 
protein binding sites. Arguslab is a molecular modeling program for windows 95/98 
system. It consists of a user interface that supports OpenGL graphics display of 
molecular structure and runs quantum mechanical calculations using the Argus 
compute server. Arguslab contains an interactive 3D molecules builder that allows the 
user to build and manipulate complex structures and a rich suite of computational 
methods, both quantum mechanical and molecular mechanical for calculating ground 
or excited states properties.  
 
3.5      PDB SUM (www.ebi.ac.uk/pdbsum) 
 
PDB sum provides summaries and analyses all the structures in the PDB. Each 
summary gives an at-a-glance overview of the contents of a PDB entry in the terms of 
resolution and R-factor, number of protein chains, ligands, metal ions, secondary 
structure, fold cartoons and ligand interactions, etc. This is vital, not only for 
visualizing the structures concealed in PDB file, but also for drawing together in a 
single resource information at the 1D (sequence), 2D (motif) and 3D (structure) 
levels. 
 
3.6        CHEMSKETCH  
 
Advanced Chemistry Development, Inc., (ACD/Labs) has developed such an 
interface, and has integrated it with every desktop software module they produce. To 
date, over 800,000 chemists have incorporated ACD/Labs' chemical drawing and 
graphics package, ACD/ChemSketch, into their daily routines. Academic institutions 
worldwide have adopted this software as an interactive teaching tool to simplify and 
convey chemistry concepts to their students, and publishing bodies such as Thieme, 
the publisher of Science of Synthesis, consider it to be "...supportive of the organic 
chemistry publisher's role, both in the construction of compounds and their basic 
analysis." 
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ACD/ChemSketch is an advanced chemical drawing tool and is the accepted 
interface for the industry's best NMR and molecular property predictions, 
nomenclature, and analytical data handling software. 
 
ACD/ChemSketch is also available as freeware, with functionalities that are highly 
competitive with other popular commercial software packages. The freeware contains 
tools for 2D structure cleaning, 3D optimization and viewing, InChI generation and 
conversion, drawing of polymers, organometallics, and Markush structures—
capabilities that are not even included in some of the commercial packages from 
other software producers. Also included is an IUPAC systematic naming capability for 
molecules with fewer than 50 atoms and 3 rings. The capabilities of 
ACD/ChemSketch can be further extended and customized by programming. 
 
The commercial version of ACD/ChemSketch offers additional capabilities above and 
beyond the freeware offering. It includes a number of advanced features including a 
dictionary of more than 158,000 trivial, common, and trade names with their 
corresponding structures. It allows the user to view SDfiles, and search Microsoft 
Word or Adobe PDF reports, SDfiles, molfiles, and CambridgeSoft ChemDraw files by 
chemical structure, substructure, or structure similarity. 
 
3.7       CORINA  
 
 CORINA is a program for the fast and efficient generation of high-quality three-
dimensional molecular models. 
Corina is a rule and data based program system, that automatically generated three 
dimensional atomic coordinates from the constitution of a molecule as expressed by a 
connection table or linear code, and which is powerful and reliable to convert large 
databases of several hundreds of compounds.  Corina is applicable to the range of 
organic chemistry.  Structures, which can be expressed in a valence bond notation 
can be processed.  It does not provide any upper limit to the size of the ring system.  
The program fully considers stereo chemical information and generates the defined 
stereo isomer.  Corina processes structures containing atoms with up to six 
neighbors; thus, even metal complexes can be processed.  It generates one low 
 27 
energy conformation for each input structure.  For ring system consisting of up to nine 
atoms, multiple conformation can be generated- a useful feature for building flexible 
3- D databases.  The program automatically detects stereo centers (tetrahedral 
centers and Cis/Trans double bonds) and is able to generate all possible isomers.  
Duplicate isomers, such as meso compounds are identified and removed as well as 
geometrically strained configurations. Corina can process a variety of standard file 
format for structure input and output (e.g.: MDL SD/ RD FILE, SMILES,  SYBYL 
MOLFILE and MOL2, PDB, Macro Model, Maestro or CIF). 
Corina delivers structures of high quality.  The RMS deviation of corina built models 
from published X-Ray structures is among the best of all commercially available 
conversion programs. It is fast, robust and provides excellent conversion rate.  Corina 
offers many features to influence the 3- D generation process.  It provides an 
interface to the ligand docking program FlexX.   
 
3.8          PUBCHEM 
 
 PubChem is a database of chemical molecules. The system is maintained by the 
National Center for Biotechnology Information (NCBI), a component of the National 
Library of Medicine, which is part of the United States National Institutes of Health 
(NIH). PubChem can be accessed for free through a web user interface. PubChem 
contains substance descriptions and small molecules with fewer than 1000 atoms and 
1000 bonds. PubChem contains its own online molecule editor with 
SMILES/SMARTS and InChI support that allows the import and export of all common 
chemical file formats to search for structures and fragments. Each hit provides 
information about synonyms, chemical properties, chemical structure including 
SMILES and InChI strings, bioactivity, and links to structurally related compounds and 
other NCBI databases like PubMed. PubChem also provides a fast chemical structure 
similarity search tool. 
PubChem Compound: Search unique chemical structures using names, synonyms or 
keywords. Links to available biological property information are provided for each 
compound.  
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PubChem Substance: Search deposited chemical substance records using names, 
synonyms or keywords. Links to biological property information and depositor web 
sites are provided.  
PubChem BioAssay: Search bioassay records using terms from the bioassay 
description, for example "cancer cell line". Links to active compounds and bioassay 
results are provided. 
Structure Search: Search PubChem's Compound database using a chemical 
structure as the query. Structures may be sketched or specified by SMILES, MOL 
files, or other formats. 
 
3.9          C@ROL 
 
C@ROL (Compound Access & Retrieval On Line) is a web-based warehouse for 
chemical compounds. C@rol stores the 2D and 3D structures as well as multiple 
conformation of a molecule. It reads different file formats for chemical structure 
registration. C@rol exports structures and data in various file formats. 
It has two major applications. 
Chemical and pharmaceutical companies can merge the products offered by various 
suppliers into one system in order to simplify and speed up the retrieval and in-house 
ordering process of chemical compounds. 
Suppliers of chemical compounds can present their products on the internet with full 
retrieval capabilities in a web-based application. 
C@ROL provides various search capabilities including innovative similarity searches 
in its chemical databases. Thus, it makes it as easy as possible to find the best offer 
for your requirements. 
3.9.1     Features 
* Web-based graphical user interface. 
 
*Graphical input of compounds by molecule editor. 
 
*Various rapid search methods for chemical structures (Structure, substructure,      
similarity, transformation, and 3D pharmacophore searches). 
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*Search methods for chemical names and properties (IUPAC name, CAS registry 
number, molecular formula, molecular weight, etc.) 
 
*Focusing the hits on a given synthesis problem or on a specific biological activity. 
 
*Various output formats for chemical structures. 
 
*Optional 3D visualization. 
 
*Integrated email functionality 
 
*Loading of databases of your choice 
 
*Administration capabilities, e.g. user management 
 
3.10     WL VIEWERLITE 
 
The WebLab Viewer is an innovative software tool for examining the 3D structure of 
molecular models, and for communicating the resulting information with colleagues.  
With the WebLab Viewer, a molecule can be viewed as a wireframe, a stick model, a 
ball and stick model, or a space-filling model.  The model can be rotated, translated, 
or scaled to any particular viewpoint.  Distances, angles, torsions, and 
stereochemistry can be easily measured; these variables are instantly updated 
whenever the local geometry is modified.  You can color or label atoms to emphasize 
different attributes. 
he WebLab Viewer reads all of the most popular molecular file formats.  In addition, 
you can paste molecules from popular 2D drawing packages such as ISIS Draw or 
ChemDraw into the Viewer.  Molecules drawn in 2D in ISIS Draw or ChemDraw are 
converted to the proper 3D geometry automatically when brought into the WebLab 
Viewer.  We can add or remove hydrogens and determine the R/S stereochemistry 
for chiral atoms. 
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The WebLab Viewer provides numerous options for advanced protein and DNA 
visualization.  Hydrogen bonds can also be displayed. The WebLab Viewer can 
create PDB and MOL files for exporting molecular information to other applications, 
VRML files for display in VRML-compliant browsers, and JPEG, GIF, and BMP files 
for use as graphics. 
 
3.11    VEGA ZZ 
 
VEGA ZZ is the evolution of the well known VEGA OpenGL package and includes 
several new features and enhancements making your research jobs very easy. VEGA 
was originally developed to create a bridge between most of the molecular software 
packages only, but in the years, enhancing its features, it's evolved to a complete 
molecular modeling suite. 
 
3.11.1   3D Features: 
Extreme OpenGL implementation for an incredible real-time rendering quality: lighting 
(4 customizable light sources + ambient light), alpha blending, hardware anti-aliasing, 
material management, 3D backgrounds. 
 Stereo view (shutter or anaglyphic glasses).  
 
 Hardware and software offline rendering. 
 
3D molecule view: wireframe with multivector bonds, CPK, ball & stick, stick, trace 
and tube. All representations can be mixed thanks to the selection tool.  
 
Atom labels.  
 
Enhanced atom coloring methods. 
  
Atom selection & picking.  
 
3D surface: dotted, mesh, solid, solid transparent. Thanks to the Hyper Drive 
technology, the calculation is very fast. The surfaces can be colored by atom, residue, 
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chain, segment, molecule, surface ID and property. The color gradient used in the 
property coloring mode can be customized by the user defining the number and the 
type of colors.  
 
Multiple surface management.  
 
All 3D objects can be managed with mouse, joystick and dials.  
 
3D interactive monitors calculated in real time (distance, angle, torsion and angle 
between two planes).  
 
Simulation trajectory visualization and animation.  
Snapshot, hardware and software image rendering with the capability to create 
images bigger than the monitor size. The software rendering includes an anti-aliasing 
algorithm with user-selectable 4x or 16x super sampling. The supported output 
formats are: BMP, GIF 256 colors, JPEG, PCX, PNG, PNM, RAW, SGI, TGA and 
TIFF.  
 
Vector graphic rendering engine. It's possible to export the view in PostScript, 
Encapsulated PostScript, PDF, LaTex, POV-Ray and VRML 2.0 formats. 
 
3.12    GENETIC OPTIMIZATION LIGAND DOCKING (GOLD) 
 
GOLD (Genetic Optimization for Ligand Docking) is a genetic algorithm for docking 
flexible ligands into protein binding sites. GOLD is an automated ligand docking 
program that uses a genetic algorithm to explore the full range of ligand 
conformational flexibility with partial flexibility of the protein, and satisfies the 
fundamental requirement that the ligand must displace loosely bound water on 
binding. Numerous enhancements and modifications have been applied to the 
original technique resulting in a substantial increase in the reliability and the 
applicability of the algorithm. The advanced algorithm has been tested on a dataset of 
100 complexes extracted from the Brookhaven Protein Data Bank. When used to 
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dock the ligand back into the binding site, GOLD achieved a 71% success rate in 
identifying the experimental binding mode. 
GOLD provides all the functionality required for docking ligands into protein binding 
sites from prepared input files. GOLD will likely be used in conjunction with a 
modeling program since you will be required to create and edit starting models, e.g. 
add all hydrogen atoms, including those necessary for defining the correct ionization 
and tautomeric states of the residues. Commonly used molecular modeling 
environments include: 
 SYBYL (http://www.tripos.com/)  
 Insight II or Cerius2 (http://www.accelrys.com/). 
Predicting how a small molecule will bind to a protein is difficult, and no program can 
guarantee success. The next best thing is to measure as accurately as possible the 
reliability of the program, i.e. the chance that it will make a successful prediction in a 
given instance. For that reason, GOLD has been tested on a large number of 
complexes extracted from the Protein Data Bank. The overall conclusion of these 
tests was that the top-ranked GOLD solution was correct in 70-80% of cases. 
 GOLD offers a choice of scoring functions, GoldScore, ChemScore and User Defined 
Score which allows users to modify an existing function or implement their own 
scoring function. With respect to using the GoldScore or ChemScore functions one 
may give a successful prediction where the other fails, but their overall success rates 
are about the same. 
Different values of the genetic algorithm parameters may be used to control the 
balance between the speed of GOLD and the reliability of its predictions. GOLD will 
only produce reliable results if it is used properly and correct atom typing for both 
protein and ligand is particularly important. 
GOLD may be used in serial or parallel modes. 
GOLD will dock each ligand several times starting each time from a different random 
population of ligand orientations. The results of the different docking runs are ranked 
by fitness score. 
The number of dockings to be performed on each ligand is set when the ligand file is 
defined. 
 By default the number of dockings to be performed on each ligand is 10. 
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The total time spent docking a ligand obviously depends on the number of docking 
runs, so you can make GOLD go faster by reducing this number. However, it is useful 
to perform at least a few docking runs on each ligand. This increases the chances of 
getting the right answer. Also, if the same answer is found in several different docking 
runs, it is usually a strong indicator that the answer is correct. 
3.12.1   GOLD features:  
A genetic algorithm (GA) for protein-ligand docking. 
Full ligand flexibility.  
Partial protein flexibility, including protein side chain and backbone flexibility for up to 
ten user-defined residues.  
Energy functions partly based on conformational and non-bonded contact information 
from the CSD.  
A choice of GoldScore, ChemScore or Astex Statistical Potential (ASP) scoring 
functions. 
Extensive options for customizing or implementing new scoring functions through a 
Scoring Function Application Programming Interface, allowing users to modify the 
GOLD scoring-function mechanism in order to: implement their own scoring function 
or enhance existing scoring functions.  
Customize docking output.  
A choice of GoldMine or SILVER for post-processing docking results.  
Automatic consideration of cavity bound water molecules.  
Improved handling and control of metal coordination geometries. 
Options for generating diverse solutions, based on RMSD.  
Automatic derivation of GA settings for particular ligands. 
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3.13    SILVER 
SILVER is a program included for use with GOLD and can be used to post-process 
docking results for large numbers of ligands. SILVER allows easy set-up and 
calculation of a variety of customizable descriptors (parameters that describe 
dockings) that quantify, amongst other things. 
 
The hydrogen-bonding interactions that occur between protein and docked ligand. 
  
The H-bond interactions that do not occur, e.g. a protein H-bond donor that is 
prevented from forming a hydrogen bond by a ligand hydrophobic group. 
  
Other close contacts between protein and ligand.  
  
The buried surface area of the ligand, or of certain types of atoms in the ligand (e.g. 
hydrophobic atoms). 
 
Whether particular regions of the binding site are occupied by the ligand. 
 
Simple properties such as the number of H-bonding ligand atoms, molecular weight of 
ligand, number of rotatable bonds. 
 
Although not its primary purpose, SILVER also serves as a browser for visualizing 
docking results from GOLD. 
3.14     Q-ALBUMIN 
Q-Albumin software takes a molecular structure and calculates HSA (Human Serum 
Albumin) binding constant by docking the molecule to both of the HSA active sites 
(Sudlow site I and Sudlow site II).         
 Drug distribution within the body is determined mainly by free (unbound) 
concentration of drug in circulating plasma. The unbound fraction, in turn, depends on 
drug absorption by plasma proteins. Human Serum Albumin (HSA) is the most 
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abundant blood plasma protein and is produced in the liver.         Quantum 
Pharmaceuticals are the vendors of Q-Albumin software and is a commercially 
available one. 
3.15     QUANTAMSOFTWARE 
          QUANTUM is a drug discovery and computational chemistry tool firmly based on 
fast ab initio molecular, quantum and statistical physics methods. The implemented 
algorithms allow to conduct calculations in complicated chemical environments including 
ions and hetgroups, with full protein and the drug candidates flexibility accounted. The 
core of QUANTUM is a docking tool useful for chemical library screening and identifying 
compounds with strong binding affinity to a given disease target.   
QUANTUM employs quantum mechanics, thermodynamics, and an advanced 
continuous water model for solvation effects to calculate ligands binding affinities. This 
approach differs dramatically from scoring functions that are commonly used for binding 
affinity predictions. By including the entropy and aqueous electrostatics contributions in 
to the calculations directly, QUANTUM algorithms produce much more accurate and 
robust values of binding free energies.  
         Interaction of a ligand with a protein is characterized by the value of binding free 
energy. The free energy (F) is the thermodynamic quantity, that is directly related to 
experimentally measurable value of inhibition constant (IC50) and depends on 
electrostatic, quantum, aqueous solvation forces, as well as on statistical properties of 
interacting molecules.  
          QUAMTUM SOFTWARE is provided by Quantum pharmaceuticals and is a 
commercial one. 
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3.16     METHODOLOGY  
The X-ray crystallographic structure of Human HDAC-8 complexed with SAHA was 
retrieved from Protein Data Bank (PDB ID: 1T69). This structure was saved as a 
standard PDB file. The ligand and the receptor protein are separated and saved in 
two different files using Swiss PDB viewer. The Smiles formula of ligand was 
retrieved from PDB and used to generate the original three dimensional structure of 
the ligand. For this the free standing molecular building tool CORINA is used. The 
active site of the protein was defined as the residues within 4Å vicinity of the ligand 
molecule with the help of PDB viewer. Preparation of active site involved correcting 
the ionization states of key amino acid side chains, adding hydrogen and listing out all 
the atoms making the active site as a text file. For this Argus Lab was used. GOLD 
(Genetic Optimization for Ligand Docking), was used for protein-ligand docking. 
GOLD (Genetic Optimization for Ligand Docking), was used for protein-ligand 
docking. The CORINA generated ligand structure was docked into the active site and 
the GoldScore was recorded. Default settings were chosen and GOLD was run under 
Standard mode. 
For screening of chemical databases, library screening settings was selected. 
Databases containing 3D structures of thousands of small molecules were 
downloaded in SDF format. The databases screened include CHEMBANK, KEGG, 
and NCTER which provided a total of around six thousand molecules. 
Top ranking molecules from the best rank file were recorded. It was followed by strict 
visualization using Pymol and “hits” were selected. These molecules were then 
docked independently for GoldScore and then ChemScore. Molecules which got high 
scores for both GoldScore and ChemScore were selected. These selected structures 
were opened in chemsketch and functional groups were added to the ligands. These 
ligands were saved as pdb format. These ligands were then taken and again docked. 
Molecules which got high scores for both GoldScore and ChemScore were selected 
and compared with the previous results. Those with best results were then taken for 
calculating H-bond interactions and close contacts in silver. Bioactivity prediction of 
the best ranked ligands was done using Quantum software. Their physicochemical 
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properties were also analyzed in Q-albumin software. Ultimately the results obtained 
were analyzed to predict the best potential ligand for HDAC-8. 
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RESULTS AND DISCUSSION 
Table 4.1: Goldscore and chemscore of the known ligands 
 
NAME  GOLDSCORE CHEMSCORE 
B3N 58.19 21.10 
SHH 66.06 20.90 
TSN 64.00 24.88 
 
Table 4.2: Goldscore and chemscore results of kegg ligands 
 
Keg id Name  Goldscore Chemscore 
C00124 Isopentenyl 
diphosphate; 
delta3-Isopentenyl 
diphosphate; 
delta3-Methyl-3-
butenyl diphosphate 
60.79 6.77 
C00341 Geranyl diphosphate 63.33 11.82 
C00404 (Phosphate)n; 
(Phosphate)n+1; 
(Phosphate)n-1 
70.55 6.69 
C00536 Triphosphate; 
Tripolyphosphate 
67.43 5.85 
C00677 Deoxynucleoside 
triphosphate 
83.87 5.59 
C02569 Neryl diphosphate; 
Neryl pyrophosphate 
64.59 11.56 
C03190 (+)-Bornyl-
diphosphate 
68.69  12.58 
C03279 Inorganic 
triphosphate 
68.43 6.67 
C04093 poly-cis-Polyprenyl 
diphosphate 
62.56 11.53 
C05308 Linaloyl diphosphate 61.72   - 
C05470 Urocortisone 62.20   - 
C05806 Polyprenyl 
diphosphate 
64.07 11.19 
 
Table 4.3: Silver results of known ligands 
 
Name Close contact with 
protein residues 
H-bonds 
B3N TYR306:OH 
 
HIS180                                              
TYR306 
SHH HIS180:ND1                                                 
HIS180:CE1 
HIS180
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Fig: 1:  Isopentenyl diphosphate; delta3-Isopentenyl diphosphate; 
delta3-Methyl-3-butenyl diphosphate (kegg c00124) 
 
 
 
Fig: 2: Geranyl diphosphate (kegg c00341) 
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Fig: 3:  (Phosphate)n; (Phosphate)n+1; (Phosphate)n-1 
 (Kegg c00404) 
 
 
 
Fig: 4: Triphosphate; Tripolyphosphate (kegg c00536) 
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Fig: 5: Deoxynucleoside triphosphate (kegg c00677) 
 
 
 
 
Fig: 6: Neryl diphosphate; Neryl pyrophosphate (kegg c02569) 
 
 
 42 
 
  
Fig: 7: (+)-Bornyl-diphosphate (kegg c03190) 
 
 
 
 
Fig: 8: Inorganic triphosphate (kegg c03279) 
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Fig: 9: poly-cis-Polyprenyl diphosphate (kegg c04093) 
 
 
 
Fig: 10: Linaloyl diphosphate (kegg c05308) 
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Fig: 11: Urocortisone (kegg c05470) 
 
 
 
Fig: 12: Polyprenyl diphosphate (kegg c05806) 
 
 
 
 45 
Table 4.4: Silver results of ligands taken from kegg database 
 
Name  Close contacts with protein 
residues 
H-bonds 
Isopentenyl diphosphate; 
delta3-Isopentenyl 
diphosphate; 
delta3-Methyl-3-butenyl 
diphosphate 
 
HIS180:CE1                                        
PHE152:CD2 
 
TYR306:H 
Geranyl diphosphate 
 
 
 
HIS142:CD2                                         
HIS180:CE1                                            
PHE152:CD2 
TYR306:H                                            
HIS180:H 
(Phosphate)n; 
(Phosphate)n+1; 
(Phosphate)n-1 
HIS143:CD2                                            
PHE208:CE1                                            
PHE152:CD2  
TYR306:H                                             
HIS180:H 
Triphosphate; 
Tripolyphosphate 
PHE152:CD2                                             
HIS143:CD2                                            
PHE208:CE1                                            
HIS180:CE1 
 
TYR306:H                                             
HIS180:H 
 
Deoxynucleoside 
triphosphate 
HIS180:CE1                                              
HIS142:NE2                                              
HIS142:CD2                                             
HIS143:CD2        
 
HIS142:H                                              
TYR306:H                                            
PHE208:H 
Neryl diphosphate; 
Neryl pyrophosphate 
HIS180:CE1                                              
PHE152:CD2                                               
PHE152:CD1                                             
PHE152:CE1 
 
TYR306:H                                           
HIS180:H
 
(+)-Bornyl-diphosphate PHE152:CD2                                             
HIS180:CE1                                              
HIS143:CD2   
TYR306:H                                           
HIS180:H 
Inorganic triphosphate PHE152:CD2                                                
HIS143:CD2                                                
HIS142:CD2                                                
PHE208:CE1  
 
TYR306:H     
                            
HIS180:H 
poly-cis-Polyprenyl 
diphosphate 
PHE152:CD2                                               
HIS180:CE1 
TYR306:H       
                                     
HIS180:H 
Linaloyl diphosphate PHE152:CD2                                         
HIS143:CD2                                           
HIS142:CD2 
TYR306:H                                      
HIS180:H 
Urocortisone HIS180:CE1                                                
PHE152:CD2                                                
PHE152:CG                                                
GLY151:CA                                                
GLY151:C    
 
TYR306:H                                          
HIS180:H                                             
PHE208:H         
Polyprenyl diphosphate 
 
 
 
TYR306:CD2                                                 
TYR306:CE1                                                 
ASP178:CG 
 
HIS180:H                                                
ASP178:H                                           
ASP267:H 
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Table 4.5: Druglikiness results of ligands taken from keg database. 
 
Keg id Name LogP Logs Lipinski’s 
rule 
C00124 Isopentenyl 
diphosphate; 
delta3-Isopentenyl 
diphosphate; 
delta3-Methyl-3-
butenyl diphosphate 
0.8 -1.0 true 
C00341 Geranyl 
diphosphate 
1.5 -2.0 true 
C00404 (Phosphate)n; 
(Phosphate)n+1; 
(Phosphate)n-1 
-0.7 0.7 true 
C00536 Triphosphate; 
Tripolyphosphate 
-0.7 0.7 true 
C00677 Deoxynucleoside 
triphosphate 
- - - 
C02569 Neryl diphosphate; 
Neryl 
pyrophosphate 
2.5 -3.2 true 
C03190 (+)-Bornyl-
diphosphate 
2.2 -2.3 true 
C03279 Inorganic 
triphosphate 
- - - 
C04093 poly-cis-Polyprenyl 
diphosphate 
2.5 -3.2 true 
C05308 Linaloyl diphosphate - - - 
C05470 Urocortisone 1.8 -3.5 true 
C05806 Polyprenyl 
diphosphate 
2.5 -3.2 true 
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Table 4.6: Properties of ligands taken from kegg database 
 
 
Keg id Name  Mol.wt H-bond 
donor 
count 
H-bond 
acceptor 
count 
C00124 Isopentenyl 
diphosphate; 
delta3-Isopentenyl 
diphosphate; 
delta3-Methyl-3-
butenyl diphosphate 
246.092102 
g/mol 
3 7 
C00341 Geranyl diphosphate 314.209122 
g/mol 
3 7 
C00404 (Phosphate)n; 
(Phosphate)n+1; 
(Phosphate)n-1 
257.954983 
g/mol 
5 10 
C00536 Triphosphate; 
Tripolyphosphate 
257.954983 
g/mol 
5 10 
C00677 Deoxynucleoside 
triphosphate 
291.6865 
g/mol 
3 5 
C02569 Neryl diphosphate; 
Neryl pyrophosphate 
314.209122 
g/mol 
3 7 
C03190 (+)-Bornyl-
diphosphate 
314.209122 
g/mol 
3 7 
C03279 Inorganic 
triphosphate 
257.954983 
g/mol 
5 10 
C04093 poly-cis-Polyprenyl 
diphosphate 
314.209122 
g/mol 
3 7 
C05308 Linaloyl diphosphate 314.209122 
g/mol 
3 7 
C05470 Urocortisone 364.47578 
g/mol 
3 5 
C05806 Polyprenyl 
diphosphate 
314.209122 
g/mol 
3 7 
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Table 4.7: Ic50 results of ligands taken from kegg database 
 
Keg id Name  Ic50 Gbind,KJ/ RMS 
C00124 Isopentenyl 
diphosphate; 
delta3-Isopentenyl 
diphosphate; 
delta3-Methyl-3-
butenyl diphosphate 
9.13e-002 -6.05 120651.00 
C00341 Geranyl 
diphosphate 
inf 2227.05 4.88 
C00404 (Phosphate)n; 
(Phosphate)n+1; 
(Phosphate)n-1 
2.91e-006 -32.22 1.88 
C00536 Triphosphate; 
Tripolyphosphate 
2.81e-006 -32.31 1.85 
C00677 Deoxynucleoside 
triphosphate 
- - - 
C02569 Neryl diphosphate; 
Neryl 
pyrophosphate 
3.95e-004 -19.81 3.46 
C03190 (+)-Bornyl-
diphosphate 
4.09e-004 -19.72 4.53 
C03279 Inorganic 
triphosphate 
- - - 
C04093 poly-cis-Polyprenyl 
diphosphate 
5.97e-004 -18.76 5.02 
C05308 Linaloyl diphosphate - - - 
C05470 Urocortisone 2.76e-001 -3.26 8.22 
C05806 Polyprenyl 
diphosphate 
4.87e-004 -19.28 5.09 
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Table 4.8: IC50 results of ligands 
Name Ic50 G bind,kj/ Rms,A 
1.1.2130 3.10e+091 532.48 1.50 
3.4.2130 1.73e+043 251.64 1.77 
9.2.2130 8.96e+010 63.66 3.42 
10.10.2130 4.45e+016 96.89 3.16 
15.2.12645 1.12e+052 302.93 2.01 
18.2.12645 4.80e+000 3.97 4.04 
19.1.12645 inf 5619.91 3.21 
23.6.2130 2.46e-002 -9.37 5.28 
2130.5 2.01e+041 240.38 2.03 
2137.1 1.28e-005 -28.48 1.09 
3039.3 1.05e-003 -17.34 1.32 
2-[[4-
(dimethylamino)phenyl]sulfonyl]-
1-[5-nitro-2-furyl]ethanone 
inf 15862.40 2.99 
 
Table 4.9: Druglikeness results 
Name LogP Logs Lipinski’s rule 
1.1.2130 4.7 -5.4 true 
3.4.2130 4.7 -5.4 true 
9.2.2130 5.1 -5.7 false 
10.10.2130 5.1 -5.7 false 
15.2.12645 0.5 -1.7 true 
18.2.12645 -0.2 -0.8 true 
19.1.12645 -0.2 -1.0 true 
23.6.2130 4.1 -4.8 true 
2130.5 5.4 -5.5 false 
2137.1 1.8 -2.9 false 
3039.3 1.7 -5.2 true 
12645.3 0.3 -1.3 True 
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Table 4.10: Goldscore and chemscore results 
 
 
Name Goldscore Chemscore  
1.1.2130 73.46 8.73 
3.4.2130 72.24 6.64 
9.2.2130 71.20 8.79 
10.10.2130 73.29 6.97 
15.2.12645 73.16 27.78 
18.2.12645 71.79 26.35 
19.1.12645 71.16 26.83 
23.6.2130 70.37 7.52 
2130 61.77 7.29 
2137 58.64 26.90 
3039 61.52 26.96 
2-[[4-
(dimethylamino)phenyl]sulfonyl]-
1-[5-nitro-2-furyl]ethanone 
70.34 29.17 
 
 
 
 
 
 
 
 
 
 
 51 
Table 4.11: Q-ALBUMIN RESULTS 
 
Name 
Albumin,    
pKd 
Site1, 
pKd 
Site2, 
pKd LogP 
 
 
 
Mol. weight 
H-bond 
acceptors 
H-bond 
Donors 
Rotatable 
Bonds Lipinski's rule 
1.1.2130 N/A N/A N/A 4.6 485.2 4 0 8 Yes 
3.4.2130 3.6 3.4 3.6 4.7 483.2 4 0 8 Yes 
9.2.2130 4.3 2 4.3 5.6 481.2 3 0 9 No 
10.10.2130 3.9 1.9 3.9 5.6 481.2 3 0 9 No 
15.2.12645 4.9 3 4.9 1.6 354.4 8 1 13 Yes 
18.2.12645 5.3 4.5 5.3 0.8 355.4 9 3 13 Yes 
19.1.12645 3.9 3.9 3.3 1 355.4 9 2 13 Yes 
23.6.2130 4.5 4.5 3.2 4.8 455.1 3 1 8 Yes 
Kegg374 6 4.9 6 -0.7 257.9 10 0 4 Yes 
Kegg491 6 4.9 6 -0.7 257.9 10 0 4 Yes 
Kegg2571 5.3 4.3 5.3 -0.7 257.9 10 0 4 Yes 
12645.3 5.2 3.8 5.2 1.9 338.3 8 0 8 Yes 
2137.1 3.2 2.3 3.2 5.4 439.1 2 0 7 No 
2130.5 4.1 4.1 3.6 2.9 323.1 7 2 5 Yes 
3039.3 4.5 4.1 4.5 1.1 391.4 6 6 11 No 
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Fig: 13: 12645 within the active site of SHH 
 
Fig: 14: methyl group added at C-4 of 12645 within the active site of SHH 
 53 
 
Fig: 15: amino group added at C-5 of 12645 within the active site of SHH 
 
Fig: 16: amino group added at C-4 of 12645 within the active site of SHH 
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The computational experiment undertaken has resulted in the identification of a few 
small molecules, which docked well in to the active site of the target. Careful visual 
inspection of the top ranked molecules (hits) yielded a list of four small molecules. 
These four molecules yielded high goldscore and chemscore value, which indicates 
the stability of the structure. When further analyses were done using ic50, 
druglikeness, albumin pkd, the results were found to lie within an optimum range. The 
docked poses, along with their corresponding GoldScore and ChemScore are given. 
These molecules are suggested to be interesting candidates for further testing in the 
laboratory. 
Table 4.12: Novel potential ligands 
Molecule name Goldscore  Chemscore  
2-[[4-
(dimethylamino)phenyl]sulfonyl]-
1-[5-nitro-2-furyl]ethanone 
70.34 29.17 
Methyl group added to 2-[[4-
(dimethylamino)phenyl]sulfonyl]-
1-[5-nitro-2-furyl]ethanone at C-
4 position 
73.16 27.78 
Amino group added to 2-[[4-
(dimethylamino)phenyl]sulfonyl]-
1-[5-nitro-2-furyl]ethanone at C-
5 position 
71.79 26.35 
Amino group added to 2-[[4-
(dimethylamino)phenyl]sulfonyl]-
1-[5-nitro-2-furyl]ethanone at C-
4 position 
71.16 26.83 
 
 
 
 55 
                               SUMMARY AND CONCLUSION 
Histone deacetylase (HDAC) and Histone acetyl-transferase (HAT) are enzymes that 
influence transcription by selectively deacetylating or acetylating the ε-amino groups 
of lysine located near the amino termini of core histone proteins. Over expression of 
HDACs noted in many forms of cancers including leukemia and breast cancer. There 
is a growing interest in the development of histone deacetylase inhibit. There is a 
growing interest in the development of histone deacetylase inhibitors as anti cancer 
agents. In this study the active site of HDAC-8 is defined as the residues which are 4 
Å vicinity of the ligand. Large databases of small molecules were computationally 
screened using molecular docking for “hits” that can conformationally and chemically 
fit to the active site. 
The study has identified four putative small molecular inhibitors that might bind well to 
the active site of the target molecule chosen for the study (HDAC-8). These 
molecules, predicted to “dock” well into the active site of human HDAC-8 should be 
considered as “interesting” molecules that need to be further tested in the laboratory. 
Finally, this purely insilico study strongly underscores the importance of 
computational approaches in drug discovery, supplementing classical methods, thus 
saving enormous amount of time and money. 
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